


**Product Name** : EC-359  
**Cat. No.** : PC-35333  
**CAS No.** : 2012591-09-0  
**Molecular Formula** : C<sub>36</sub>H<sub>38</sub>F<sub>2</sub>O<sub>2</sub>  
**Molecular Weight** : 571.715  
**Target** : Other Targets  
**Solubility** : 10 mM in DMSO



## Biological Activity

EC-359 (EC359) is a first-in-class, orally available inhibitor of **leukemia inhibitory factor (LIF)**, blocks LIF-LIFR interaction and binds to LIFR with affinity of 81 nM in SPR assay.

EC-359 displays limited binding to classical steroid receptors.

EC-359 shows cytoskeletal disruption and targeting cancer-associated fibroblasts (CAFs) through inhibition of alpha-SMA but not beta-tubulin, reduces the STAT3 phosphorylation, mTOR and further downstream signaling cascades.

EC-359 dose dependently reduces tumor burden in both TNBC xenograft and murine syngeneic MM51 models (1 and 5 mg/kg dose).

## References

Hareesh B. Nair, et al. Abstract LB-B04: Development of a first-in-class leukemia inhibitory factor (LIF)/LIFR inhibitor, EC359 for targeted therapy

**Caution: Product has not been fully validated for medical applications. Lab Use Only!**

E-mail: tech@probechem.com